Multicenter study of the efficacy, cycle control and tolerability of a phasic desogestrel-containing oral contraceptive

REFERENCES

• Meade T W, Greenberg G, Thompson S G. Progestogens and cardiovascular reactions associated with oral contraceptives and comparison of the 50 and 30 μg preparations. Br Med J 1980; 1: 1157–61
   Google Scholar
• Kay C R. Progestogens and arterial disease – evidence from the Royal College of General Practitioners’ study. Am J Obstet Gynecol 1982; 142: 762–5
   PubMed Web of Science ®Google Scholar
• Vessey M P, Mant D, Smith A, et al. Oral contraceptives and venous thromboembolism findings in a large prospective study. Br Med J 1986; 292: 526
   PubMed Web of Science ®Google Scholar
• Gerstmann B B, Piper J M, Tomita D K, et al. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133: 32–7
   PubMed Web of Science ®Google Scholar
• Pasquale S A. Rationale for a triphasic oral contraceptive. J Reprod Med 1984; 19: 560–7
   Google Scholar
• Wynants P, Ide P. Endometrial morphology during a normophasic and triphasic regimen: a comparison. Contraception 1986; 33: 149–57
   PubMed Web of Science ®Google Scholar
• Young R L, Snabes M C, Frank M L, et al. A randomized, double-blind, placebo-controlled comparison of the impact of low-dose and triphasic oral contraceptives on follicular development. Am J Obstet Gynecol 1992; 167: 678–82
   PubMed Web of Science ®Google Scholar
• Ulstein M, Svendsen E, Steier A. Clinical experience with a triphasic oral contraceptive. Acta Obstet Gynecol Scand 1984; 63: 233–6
   PubMed Web of Science ®Google Scholar
• Skouby S O. Oral contraception with a triphasic combination of gestodene and ethinylestradiol: results of a multicenter clinical study. Int J Fertil 1987, Suppl: 45–8
   PubMedGoogle Scholar
• Christie T. A clinical overview of a new triphasic contraceptive containing gestodene. Int J Fertil 1989, Suppl: 40–9
   PubMedGoogle Scholar
• Gauthier A, Upmalis D, Dain M P. Clinical evaluation of a new triphasic oral contraceptive: norgestimate and ethinylestradiol. Acta Obstet Gynecol Scand 1992; 71(Suppl 156)27–32
   Google Scholar
• Weber-Diehl F, Unger R, Lachnit U. Triphasic combination of ethinyl estradiol and gestodene. Contraception 1992; 46: 19–27
   PubMed Web of Science ®Google Scholar
• Newton J R. Classification and comparison of oral contraceptives containing new generation progestogens. Hum Reprod Update 1995; 1: 231–63
   PubMed Web of Science ®Google Scholar
• Bilotta P, Favilli S. Clinical evaluation of a monophasic ethinylestradiol/desogestrel-containing oral contraceptive. Arzneimittelforschung 1988; 38: 932–4
   PubMed Web of Science ®Google Scholar
• Rekers H. Multicenter trial of a monophasic oral contraceptive containing ethinylestradiol and desogestrel. Acta Obstet Gynecol Scand 1988; 67: 171–4
   PubMed Web of Science ®Google Scholar
• Lammers P, Op ten Berg M. Phase III clinical trial with a new oral contraceptive containing 150 μg desogestrel and 20 μg ethinylestradiol. Acta Obstet Gynecol Scand 1991; 70: 497–500
   PubMed Web of Science ®Google Scholar
• Fotherby K. Clinical experience and pharmacological effects of an oral contraceptive containing 20 mcg oestrogen. Contraception 1992; 46: 477–88
   PubMed Web of Science ®Google Scholar
• Fotherby K. Twelve years of clinical experience with an oral contraceptive containing 30 mcg ethinyl-oestradiol and 150 mcg desogestrel. Contraception 1995; 51: 3–12
   PubMed Web of Science ®Google Scholar
• Serfaty D, Vree M L. A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 μg ethinylestradiol and either 150 μg desogestrel or 75 μg gestodene. Eur J Contracept Reprod Health Care 1998; 3: 179–89
   PubMedGoogle Scholar
• Van der Does J, Exalto N, Dieben T, et al. Ovarian activity suppression by two different low-dose triphasic oral contraceptives. Contraception 1995; 52: 357–61
   PubMed Web of Science ®Google Scholar
• Carr B R. Cycle control with desogestrel-containing oral contraceptives - comparison of a monophasic and triphasic regimen. Int J Fertil 1993; 38: 274–9
   Google Scholar
• Shoupe D. Multicenter randomized comparative trial of two low-dose triphasic combined oral contraceptives containing desogestrel ornorethindrone. Obstet Gynecol 1994; 83: 679–85
   PubMed Web of Science ®Google Scholar
• Darney P. Safety and efficacy of a triphasic oral contraceptive containing desogestrel: results of three multi-center trials. Contraception 1993; 48: 323–37
   PubMed Web of Science ®Google Scholar
• Corson S I. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand 1990; 152(Suppl)25–32
   Google Scholar
• Friedman A J, Wheeler J. Efficacy and safety of ethynodiol acetate, 1 mg, with ethinylestradiol, 35 μg, with an emphasis on contraceptive efficacy - a phase IV trial. J Reprod Med 1991; 36: 328–33
   PubMed Web of Science ®Google Scholar
• London R S, Chapdelaine A, Upmalis D, et al. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. Acta Obstet Gynecol Scand 1992; 71(Suppl 156)9–14
   Google Scholar
• Brill K. The influence of different modern low-dose oral contraceptives in intermenstrual bleeding. Adv Contracept 1991; 7(Suppl 2)51–61
   Google Scholar
• Kafrissen M E. A norgestimate-containing oral contraceptive: review of clinical studies. Am J Obstet Gynecol 1992; 167: 1196–202
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Adverse Reaction Dictionary Version 3. WHO Collaborating Centre for International Drug Monitoring, UppsalaSweden 1996
   Google Scholar
• Runnebaum B, Grunwald K, Rabe T. The efficacy and tolerability of norgestimate/ethinyl estradiol (250 μg of norgestimate/35 μg of ethinyl estradiol): results of an open, multicenter study of 59,701 women. Am J Obstet Gynecol 1992; 166: 1963–8
   PubMed Web of Science ®Google Scholar
• Andolsek K M. Cycle control with triphasic norgestimate and ethinylestradiol, a new oral contraceptive agent. Acta Obstet Gynecol Scand 1992; 71(Suppl 156)22–6
   PubMedGoogle Scholar
• Jick H, Jick S S, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589–93
   PubMed Web of Science ®Google Scholar
• Spitzer W O, Lewis M A, Heinemann L AJ, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 1996; 312: 83–8
   PubMed Web of Science ®Google Scholar
• World Health Organization. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolism. Lancet 1995; 346: 1582–8
   PubMed Web of Science ®Google Scholar
• Farmer R DT, Lawrenson R. Utilization patterns of oral contraceptives in UK general practice. Contraception 1996; 53: 211–15
   PubMed Web of Science ®Google Scholar
• Heinemann L AJ, Lewis M A, Assmann A, et al. Could preferential prescribing and referral behaviour of physicians explain the elevated thrombosis risk found to be associated with third generation oral contraceptives?. Pharmacoepidemiol Drug Saf 1996; 5: 285–94
   PubMedGoogle Scholar
• Jamin C, De Mouzon J. Selective prescribing of third generation oral contraceptives (OCs). Contraception 1996; 54: 55–6
   PubMed Web of Science ®Google Scholar
• Lewis M A, Heinemann L AJ, MacRae K D, et al. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception 1996; 54: 5–13
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø. The influence of thrombotic risk factors when oral contraceptives are prescribed: a control-only study. Acta Obstet Gynecol Scand 1997; 76: 252–60
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø, Milsom I. Oral contraceptives and thrombotic diseases: impact of new epidemiological studies. Contraception 1996; 53: 135–9
   PubMed Web of Science ®Google Scholar
• Van Lunsen H W. Recent oral contraceptive use patterns in four European countries: evidence for selective prescribing of oral contraceptives containing third-generation progestogens. Eur J Contracept Reprod Health Care 1996; 1: 39–45
   PubMedGoogle Scholar
• Westhoff C L. Oral contraceptives and venous thromboembolism: should epidemiologic associations drive clinical decision making?. Contraception 1996; 54: 1–3
   PubMed Web of Science ®Google Scholar
• Farmer R DT, Lawrenson R A, Thompson C R, et al. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83–8
   PubMed Web of Science ®Google Scholar
• Farmer R DT, Todd J-C, Lewis M A, et al. The risks of venous thromboembolic disease among German women using oral contraceptives: a database study. Contraception 1998; 57: 67–70
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø, EdstrØm B, Kreiner S. Oral contraceptives and venous thromboembolism: a case–control study. Contraception 1998; 57: 291–301
   PubMed Web of Science ®Google Scholar
• Lewis M A, MacRae K D, Kühl-Habich D, et al. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999; 14: 1493–9
   PubMed Web of Science ®Google Scholar
• Suissa S, Blais L, Spitzer W O, et al. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56: 141–6
   PubMed Web of Science ®Google Scholar
• Ulstein M, Svendsen E, Steier A. Clinical experience with a triphasic oral contraceptive. Acta Obstet Gynecol Scand 1984; 63: 233–6
   PubMed Web of Science ®Google Scholar